A modified IL-18 drug in combination with CTLA-4 blockade enhances anti-tumor efficacy in preclinical models of renal cell carcinoma

被引：0

作者：

Schoenfeld, David ^{[1
]}

Djureinovic, Dijana ^{[1
]}

Zhang, Lin ^{[1
]}

Mann, Jacqueline ^{[1
]}

Huck, John ^{[2
]}

Jilaveanu, Lucia ^{[1
]}

Ring, Aaron ^{[2
]}

Kluger, Harriet ^{[1
]}

机构：

[1] Yale Sch Med, Sect Med Oncol, New Haven, CT USA

[2] Yale Sch Med, Dept Immunobiol, New Haven, CT USA

来源：

ONCOLOGIST | 2023年 / 28卷

关键词：

IL-18; cytokines; immune-checkpoint inhibitors; anti-CTLA-4; preclinical models; RCC;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：S7 / S7

页数：1

共 50 条

[41] IL-4 enhances NKT cell-mediated IFN-γ production and anti-tumor immunity against murine renal cancer in α-galactosylceramide injected mice
Minami, K
Yanagawa, Y
Harabayashi, T
Shinohara, N
Onoe, K
Nonomura, K
JOURNAL OF UROLOGY, 2005, 173 (04): : 176 - 177
[42] Allosteric MEK inhibitor BAY 86-9766 (RDEA119) shows anti-tumor efficacy in mono-and combination therapy in preclinical models of hepatocellular carcinoma and pancreatic cancer
Puehler, F.
Scholz, A.
Kissel, M.
Adjei, A.
Miner, J. N.
Hitchcock, M.
Schmieder, R.
Mumberg, D.
Ziegelbauer, K.
EJC SUPPLEMENTS, 2010, 8 (07): : 53 - 53
[43] Phosphodiesterase 4D depletion enhances anti-tumor effects of tyrosine kinase inhibitor in renal cell carcinoma involving CRAF-ERK pathway.
Cao, Minghua
Ajay, Amrandra K.
Gasser, Martin
Hsiao, Li-Li
Waaga-Gasser, Ana Maria
CANCER RESEARCH, 2021, 81 (13)
[44] PDE4D targeting enhances anti-tumor effects of sorafenib in clear cell renal cell carcinoma and attenuates MAPK/ERK signaling in a CRAF-dependent manner
Cao, Minghua
Nawalaniec, Karol
Ajay, Amrendra K.
Luo, Yueming
Moench, Romana
Jin, Yanfei
Xiao, Sheng
Hsiao, Li-Li
Waaga-Gasser, Ana Maria
TRANSLATIONAL ONCOLOGY, 2022, 19
[45] Blockade of CD25 reduces regulatory T cell expansion and some manifestations of IL-2 mediated toxicity but does not improve anti-tumor efficacy in animal models of IL-2 immunotherapy
Harding, Fiona A.
Alvarez-Jares, Hamsell
Belmar, Nicole
Choi, Donghee
Forsyth, Charles
Fox, Melvin
Sheridan, James
Stickler, Marcia
Tang, Anthony
Hollenbaugh, Diane
JOURNAL OF IMMUNOLOGY, 2018, 200 (01):
[46] Preclinical efficacy data of MGN1601, a tumor vaccine comprising 4-fold gene-modified and irradiated allogeneic tumor cells in combination with a DNA-based immunomodulator for the treatment of metastatic renal carcinoma
Volz, B.
Schmidt, M.
Kapp, K.
Schroff, M.
Tschaika, M.
Wittig, B.
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
[47] Efficacy of PEGylated human IL-10 (AM0010) in combination with anti-PD-1 blockade in patients (pts) with metastatic renal cell carcinoma (mRCC): A phase 1b trial
Naing, A.
Infante, J.
Wong, D.
Korn, W. M.
Aljumaily, R.
Papadopoulos, K.
Autio, K.
Pant, S.
Bauer, T.
Drakaki, A.
Daver, N.
Hung, A.
Van Vlasselaer, P.
Oft, M.
Tannir, N.
ANNALS OF ONCOLOGY, 2017, 28
[48] PRO1160, a novel CD70-directed antibody-drug conjugate, demonstrates robust anti-tumor activity in mouse models of renal cell carcinoma and non-Hodgkin lymphoma
Wang, Lei
Liu, Haidong
Shang, Xiao
Han, Tae
Zhao, Baiteng
CANCER RESEARCH, 2022, 82 (12)
[49] Impact of dosing schedule and dosing sequence on anti-tumor efficacy of combination therapy with the antiangiogenic agent (AA) axitinib (AG-013736) in xenograft tumor models of human pancreatic carcinoma and non-small cell lung cancer (NSCLC)
Hu-Lowe, Dana
Mathias, Adam
Hall, Chassidy
Chen, Enhong
Zhang, Lianglin
Mullin, Robert
Hollister, Beth
Christensen, Jamie
CANCER RESEARCH, 2009, 69
[50] An open-label, single-center phase II trial of cadonilimab (an anti-PD-1/CTLA-4 bispecific antibody) in combination with platinum-based dual-drug neoadjuvant chemotherapy for locally advanced, resectable head and neck squamous cell carcinoma
Cao, Fei
Wu, Di
Xu, PengFei
Fang, Qi
Zhao, Zheng
Zhang, Xinrui
Yan, Honghong
Jiang, Ke
Zhou, Jian
Li, Yan
Lu, Li-Xia
Chen, Chunyan
Han, Fei
Li, Zhiming
Liu, Xuekui
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)

← 1 2 3 4 5 →